PT-141 (Bremelanotide / Vyleesi) is a cyclic heptapeptide melanocortin receptor agonist. FDA-approved for HSDD in premenopausal women. Unlike PDE-5 inhibitors, it acts centrally through MC3R and MC4R receptors in the hypothalamus u2014 increasing dopaminergic signalling in reward and arousal pathways. Effective in both women and men.
Overview
Reconstitution Table (5 mL mL BAC water u2192 10 mg)
| Dose | Draw (U-100) | Timing |
| 1 mg starting | 5 Units | 45 min before activity |
| 1.75 mg standard | ~9 Units | 45 min before activity |
Reconstitute 10 mg with 5 mL BAC water u2192 2 mg/mL. 1.75 mg = ~8.75 Units. Administer SC to abdomen 45u201390 min before desired effect. Do not exceed 2 doses per week.
FDA-approved as Vyleesi for HSDD. Off-label use in men for erectile dysfunction and performance is not approved. Avoid in cardiovascular disease. Research and clinical use only.
Potential Benefits & Side Effects
Potential Benefits
- Enhanced sexual desire (FDA-proven for HSDD)
- Central mechanism (not vascular)
- Rapid onset (~45 min)
- Effective in both sexes (studies)
Possible Side Effects
- Nausea (most common u2014 pre-treat with anti-emetic)
- Flushing
- Transient blood pressure elevation
- Hyperpigmentation (long-term, high dose)
- Fatigue
Storage Instructions
Lyophilized Powder
- Short-term (<3 months): Refrigerate at 2u00b0Cu20138u00b0C
- Long-term: Freeze at u221220u00b0C or lower
- Protect from light and moisture
- Allow vial to reach room temperature before opening
Reconstituted Solution
- Refrigerate at 2u00b0Cu20138u00b0C u2014 do not freeze
- Use within 28 days when reconstituted with BAC water
- Always use sterile technique when drawing doses
References
Important Note
This protocol guide is for educational and research purposes only. It is not medical advice. Always consult a qualified healthcare professional before using any peptide compound.